Published on 23/12/2025

Zoonotic Risk Assessment Case Studies

Understanding Zoonotic Risk Assessment in Veterinary Regulatory Submissions

Zoonotic diseases pose significant challenges not only to animal health but also to public health. They are pathogens that can be transmitted from animals to humans, which emphasizes the importance of rigorous evaluations in veterinary product submissions. Understanding the framework of zoonotic risk assessment is critical for regulatory compliance in the United States (US), European Union (EU), and the United Kingdom (UK).

In this tutorial, we will explore the key components of zoonotic risk assessment within the context of regulatory submissions. We will detail the methodologies, case studies, and best practices, while also focusing on relevant regulations through agencies such as the FDA’s Center for Veterinary Medicine (CVM), the European Medicines Agency (EMA) for veterinary products, and other international regulatory bodies.

Step 1: The Framework of Zoonotic Risk Assessment

Before diving into case studies, it is essential to understand the framework and components involved in a zoonotic risk assessment. Generally, this involves the identification of potential zoonotic agents, their transmission routes, and the populations at risk — both animal and human.

The framework typically encompasses the following categories:

• Hazard Identification: Identifying zoonotic pathogens associated with the veterinary product, including microbiological and clinical data.
• Exposure Assessment: Evaluating the potential for human exposure to the pathogen through various routes via the veterinary product.
• Risk Characterization: Assessing the consequences of exposure, including both the severity and likelihood of adverse effects in humans.
• Risk Management Strategies: Implementing controls and management strategies to mitigate identified risks.

Step 2: Regulatory Expectations and Guidelines

Different regulatory agencies have established protocols and guidelines for conducting zoonotic risk assessments. Each agency’s requirements may differ slightly but share common objectives.

For the FDA, key guidance documents from the CVM outline protocols for hazard analysis and risk assessment in animal drugs. In the EU, the Veterinary Medicinal Products Regulation lays out the requirements to ensure the safety and efficacy of veterinary products while considering public health implications. In the UK, post-Brexit regulatory frameworks still align closely with EU standards but are evolving.

Understanding these regulatory expectations is vital during the submission process. Companies offering zoonotic risk assessment regulatory consulting services should ensure compliance with these guidelines to facilitate smoother review processes and approvals.

Step 3: Case Studies — Applying Zoonotic Risk Assessment

Real-world case studies provide invaluable insights into how zoonotic risk assessments are conducted in practice. Below, we will discuss several important cases that illustrate the complexities and methodologies involved in these assessments.

Case Study 1: Assessment of a Vaccination Product for Cats

This case examines the development of a feline vaccination product. The manufacturer was required to conduct a detailed zoonotic risk assessment given the potential transmission of pathogens from cats to humans, such as toxoplasmosis.

The hazard identification phase revealed that the vaccine did not contain live pathogens that could infect humans. Nonetheless, the exposure assessment accounted for the scenarios in which cat owners might interact with their pets during and after vaccination. Risk characterization identified minor risks associated with the manufacturing and handling processes.

Substantial risk management plans were put into place, including warning labels and guidelines for safe handling and post-vaccination interactions. This case highlights the importance of comprehensive risk assessment methodologies and effective communication to mitigate risks.

Case Study 2: Antiparasitic Product for Livestock

This case involves the submission of an antiparasitic product intended for cattle. Given the potential for zoonotic transmission of parasitic diseases such as leptospirosis, a thorough zoonotic risk assessment was critically relevant.

The manufacturer conducted a hazard identification review, which noted several potential zoonotic risks, including exposure through occupational handling and consumption of products from treated animals. Assessing exposure pathways was crucial; thus, specific scenarios in which farm workers may come into contact with the treatment were evaluated.

In the risk characterization phase, the assessments indicated a low likelihood of significant human infection through properly managed livestock. Risk mitigation strategies were employed, including guidelines on proper usage, withdrawal periods, and full compliance with regulations established by EMA veterinary guidelines.

Step 4: Best Practices for Conducting Zoonotic Risk Assessments

Implementing best practices during zoonotic risk assessments can enhance the regulatory submission process. Companies should consider the following strategies while preparing their submissions:

• Interdisciplinary Collaboration: Effective zoonotic risk assessments often require interdisciplinary approaches combining expertise in veterinary medicine, microbiology, epidemiology, and public health.
• Consistent Documentation: Comprehensive documentation of the entire assessment process, from hazard identification to risk management, is essential in demonstrating compliance and enhancing the credibility of submissions.
• Stakeholder Engagement: Engaging relevant stakeholders, including public health officials and veterinarians, can provide vital insights and add robustness to the assessment process.
• Continuous Monitoring: Post-market surveillance of veterinary products should be instituted to monitor any adverse effects, ensuring continuous improvement of risk management strategies.

Step 5: Preparing for Regulatory Submissions

Comprehensive planning and preparation are essential for successful regulatory submissions related to zoonotic risk assessments. The following stages should be carefully navigated:

• Compilation of Relevant Data: Gather all required information, including preclinical and clinical data, hazard assessments, and any previous submissions that may help illustrate the safety and efficacy of the product.
• Adherence to Format and Guidelines: Follow agency-specific submission formats and guidelines meticulously. This ensures that the documentation is consistent and aligned with regulatory expectations.
• Consultation with Experts: Utilizing external consultants specializing in zoonotic risk assessment regulatory consulting services can guide submissions through complicated regulatory landscapes, adding essential expertise.
• Submission Review: Perform internal reviews and consultations before final submission to identify potential issues proactively, ensuring that the submission is as robust as possible.

Conclusion: The Importance of Zoonotic Risk Assessment in Veterinary Products

Conducting thorough zoonotic risk assessments is essential for safeguarding public health while promoting animal health. This tutorial has provided a comprehensive overview of how to effectively conduct these assessments in the context of regulatory submissions, with a specific focus on case studies relevant to veterinary products.

By following the steps outlined, consulting with experts, and adhering to regulatory guidelines established by agencies such as the ICH, FDA CVM, EMA, and others, stakeholders in the veterinary industry can enhance their compliance and ultimately contribute to safer animal and human health outcomes.